Propeller Health Sensor to Be Co-Packaged With Recently Approved Enerzair® Breezhaler® Asthma Medication in Europe
(World News USA)

MADISON, Wis.--(BUSINESS WIRE)--Jul 7, 2020-- Propeller Health today announced a collaboration with Novartis to co-package the Propeller digital health platform with Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently approved Novartis medication developed to treat uncontrolled asthma. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200706005585/en/ An industry first: Propeller Health digital health solution packaged and prescribed with Enerzair Breezhaler inhaler by Novartis. (Photo: Business Wire) This collaboration marks the first time a digital health tool...